Salix Coronary Plaque vs Cleerly ISCHEMIA
AI Verdict
Choose Salix Coronary Plaque if…
Choose Salix Coronary Plaque if your primary need is a rapid, point-of-care assessment of coronary artery plaque and stenosis directly from CCTA scans. This tool is ideal for quickly identifying and quantifying various plaque types, including high-risk features, to aid in the immediate diagnosis and risk stratification of coronary artery disease. It excels in scenarios requiring detailed anatomical plaque characterization and calcium scoring for prompt clinical decision-making.
View Salix Coronary Plaque →Choose Cleerly ISCHEMIA if…
Choose Cleerly ISCHEMIA if your focus extends beyond anatomical plaque assessment to include the non-invasive determination of coronary artery ischemia at a vessel level. This tool is particularly well-suited for personalized diagnosis and treatment planning, leveraging AI-enabled CCTA analysis to estimate fractional flow reserve (FFR) and provide insights into the functional significance of lesions. It's beneficial when a comprehensive understanding of both plaque characteristics and the likelihood of ischemia is crucial for guiding patient management.
View Cleerly ISCHEMIA →For a physician evaluating AI tools for coronary artery disease, Salix Coronary Plaque and Cleerly ISCHEMIA offer distinct strengths. Salix Coronary Plaque excels in rapid, point-of-care assessment of plaque and stenosis directly from CCTA scans, providing near real-time insights into plaque characteristics and calcifications. It is particularly suited for practices prioritizing immediate, detailed plaque quantification and high-risk feature identification to aid in quick diagnostic decisions.
Conversely, Cleerly ISCHEMIA focuses on determining the likelihood of coronary artery ischemia at a vessel level, leveraging AI for non-invasive fractional flow reserve (FFR) estimation. This tool is ideal for physicians seeking to understand the functional significance of plaque and stenosis, informing personalized treatment plans based on ischemia risk. The key practical difference lies in their primary output: Salix emphasizes detailed anatomical plaque characterization and stenosis, while Cleerly prioritizes the functional impact of disease through ischemia likelihood. Physicians needing immediate, comprehensive plaque morphology and stenosis assessment may lean towards Salix Coronary Plaque. Those requiring insights into the functional implications of coronary disease and ischemia likelihood for treatment planning may find Cleerly ISCHEMIA more aligned with their needs.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Salix Coronary Plaque | Cleerly ISCHEMIA |
|---|---|---|
| Pricing | Contact for pricing | Contact for details |
| Deployment | Cloud | Web-based platform; data transfer via Cleerly Proxy (VPN or virtual appliance) |
| FDA Status | Yes AI-estimated | 1 AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Salix Coronary PlaqueTool A emphasizes a highly streamlined user experience with 'near real-time, point-of-care assessment' and claims assessments are available in less than 10 minutes without requiring multiple systems. It also highlights integrated workflow management and direct physician control without external reading teams, suggesting superior efficiency and ease of use.
Clinical Value
Cleerly ISCHEMIAWhile both tools offer significant clinical value, Tool B distinguishes itself by providing 'Non-invasive fractional flow reserve (FFR) estimation' and 'Vessel-level ischemia likelihood determination'. This functional assessment of ischemia, validated against invasive FFR in multiple clinical trials, offers a more advanced and direct measure for guiding treatment decisions compared to Tool A's focus on anatomical plaque characterization.
Pricing & Value
Salix Coronary PlaqueTool A provides greater transparency regarding its economic value by explicitly stating a US CPT reimbursement rate of US$950 per assessment for its plaque module, effective January 1, 2026. While Tool B also has a Category I CPT code for FFR estimation, its pricing details are less transparent, making Tool A's value proposition clearer for providers.
Enterprise Readiness
Cleerly ISCHEMIATool B explicitly confirms HIPAA compliance and the availability of a Business Associate Agreement (BAA), which are critical assurances for enterprise adoption in healthcare. Its use of a 'Cleerly Proxy (VPN or virtual appliance)' for data transfer further demonstrates a robust and secure approach to integration within enterprise IT environments.
Innovation
Cleerly ISCHEMIABoth tools are innovative, but Tool B's 'Non-invasive fractional flow reserve (FFR) estimation' and 'Vessel-level ischemia likelihood determination' represent a more advanced innovation by providing functional assessment of coronary artery disease. This moves beyond anatomical plaque characterization to directly inform treatment decisions, offering a less invasive yet highly accurate alternative to traditional methods.
Support & Docs
Cleerly ISCHEMIATool B provides more specific details regarding its support, outlining client support hours (Monday-Friday, 10 am ET to 6 pm ET) and offering a dedicated form for technical support requests for existing users. Tool A mentions a user guide and general technical support, but without the same level of detail.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Salix Coronary Plaque | Cleerly ISCHEMIA |
|---|---|---|
| Product Name | Salix Coronary Plaque | Cleerly ISCHEMIA |
| Company | Artrya Limited | Cleerly |
| Primary AI Focus | Near real-time, point-of-care assessment of coronary artery plaque and stenosis from CCTA scans, aiding in the rapid and accurate diagnosis of coronary artery disease. Key features include detection and quantification of coronary plaque and identification of high-risk plaque features. | Analyzes CCTA scans to non-invasively determine the likelihood of coronary artery ischemia at a vessel level, aiding physicians in personalized diagnosis and treatment planning for heart disease. Key features include non-invasive fractional flow reserve (FFR) estimation and vessel-level ischemia likelihood determination. |
| Stenosis Assessment | Stenosis assessment | Stenosis severity assessment |
| Report Generation | Automated report generation (editable) | Comprehensive interactive web-based reports |
Videos
Demos, reviews, and walkthroughs featuring Salix Coronary Plaque and Cleerly ISCHEMIA.
Frequently Asked Questions
More Comparisons
More matchups featuring Salix Coronary Plaque or Cleerly ISCHEMIA
Backers
Who funded each tool's parent company.